JP2023510746A5 - - Google Patents

Info

Publication number
JP2023510746A5
JP2023510746A5 JP2022541815A JP2022541815A JP2023510746A5 JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5 JP 2022541815 A JP2022541815 A JP 2022541815A JP 2022541815 A JP2022541815 A JP 2022541815A JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5
Authority
JP
Japan
Prior art keywords
compound according
cancer
compound
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022541815A
Other languages
English (en)
Japanese (ja)
Other versions
JP7706456B2 (ja
JP2023510746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012683 external-priority patent/WO2021142247A1/en
Publication of JP2023510746A publication Critical patent/JP2023510746A/ja
Publication of JP2023510746A5 publication Critical patent/JP2023510746A5/ja
Application granted granted Critical
Publication of JP7706456B2 publication Critical patent/JP7706456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022541815A 2020-01-10 2021-01-08 Smarca2-vhl分解剤 Active JP7706456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959502P 2020-01-10 2020-01-10
US62/959,502 2020-01-10
PCT/US2021/012683 WO2021142247A1 (en) 2020-01-10 2021-01-08 Smarca2-vhl degraders

Publications (3)

Publication Number Publication Date
JP2023510746A JP2023510746A (ja) 2023-03-15
JP2023510746A5 true JP2023510746A5 (cg-RX-API-DMAC7.html) 2024-01-16
JP7706456B2 JP7706456B2 (ja) 2025-07-11

Family

ID=74495106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541815A Active JP7706456B2 (ja) 2020-01-10 2021-01-08 Smarca2-vhl分解剤

Country Status (7)

Country Link
US (1) US20230091042A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087658B1 (cg-RX-API-DMAC7.html)
JP (1) JP7706456B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021205326B2 (cg-RX-API-DMAC7.html)
CA (1) CA3167166A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022008487A (cg-RX-API-DMAC7.html)
WO (1) WO2021142247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
MX2023001445A (es) * 2020-08-04 2023-05-08 Aurigene Oncology Ltd Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)

Similar Documents

Publication Publication Date Title
TW384288B (en) 5-substituted derivatives of mycophenolic acid
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2010505930A5 (cg-RX-API-DMAC7.html)
JP2009507909A5 (cg-RX-API-DMAC7.html)
JP2020508310A5 (cg-RX-API-DMAC7.html)
JP7205830B2 (ja) 新規アントラニル酸系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤
JP2006526590A5 (cg-RX-API-DMAC7.html)
JP2020534264A5 (cg-RX-API-DMAC7.html)
JP2009538327A5 (cg-RX-API-DMAC7.html)
JP2024509981A5 (cg-RX-API-DMAC7.html)
JP2006501201A5 (cg-RX-API-DMAC7.html)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
US10172814B2 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
JP2007529426A5 (cg-RX-API-DMAC7.html)
JP7229482B2 (ja) 新規アミド系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤
JP2013544794A5 (cg-RX-API-DMAC7.html)
WO2002006249A1 (en) Method for producing 1-substituted-1,2,3-triazole derivative
US10093609B2 (en) TAK1 kinase inhibitors, compositions, and uses related thereto
CA3167918A1 (en) Compositions and methods for modulating cancer
TW422834B (en) Butyrate prodrugs for increasing fetal hemoglobim and promoting cell differenfiation and pharmacentical compositions comprising the same
JP2017513934A5 (cg-RX-API-DMAC7.html)
WO2002074296A1 (en) Remedies for solid cancer containing hydroxamic acid derivatives as the active ingredient
TW202340142A (zh) Gcl抑制劑
JP2004528311A5 (cg-RX-API-DMAC7.html)
JP2023541840A5 (cg-RX-API-DMAC7.html)